Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PAVmed (PAVM) Shares Outstanding (Weighted Average) (2022 - 2025)

Historic Shares Outstanding (Weighted Average) for PAVmed (PAVM) over the last 4 years, with Q3 2025 value amounting to $21.6 million.

  • PAVmed's Shares Outstanding (Weighted Average) changed N/A to $21.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.6 million, marking a year-over-year change of. This contributed to the annual value of $9.7 million for FY2024, which is 3375.01% up from last year.
  • Per PAVmed's latest filing, its Shares Outstanding (Weighted Average) stood at $21.6 million for Q3 2025.
  • PAVmed's 5-year Shares Outstanding (Weighted Average) high stood at $89.8 million for Q3 2022, and its period low was $5.9 million during Q4 2022.
  • In the last 4 years, PAVmed's Shares Outstanding (Weighted Average) had a median value of $9.4 million in 2024 and averaged $27.0 million.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first plummeted by 9250.26% in 2023, then skyrocketed by 9758.56% in 2025.
  • Quarter analysis of 4 years shows PAVmed's Shares Outstanding (Weighted Average) stood at $5.9 million in 2022, then increased by 21.78% to $7.2 million in 2023, then surged by 33.75% to $9.7 million in 2024, then surged by 122.85% to $21.6 million in 2025.
  • Its last three reported values are $21.6 million in Q3 2025, $18.1 million for Q2 2025, and $13.9 million during Q1 2025.